Eli Lilly's Zepbound is the first and only approved dual GLP-1/GIP agonist, and Lilly is also working on its own triple ...

The Danish pharma company said it would pay $200 million upfront and up to $1.8 billion in milestone payments to United Laboratories International for the rights to UBT251, a drug in early-stage ...

“We look forward to building on United Biotechnology’s scientific work and further exploring the potential best-in-class properties of UBT251 across cardiometabolic disease indications.

Novo Nordisk has signed an exclusive global licensing deal worth up to $2 billion for UBT251, a weight-loss drug developed by China-based The United Laboratories International Holdings Limited ...

What's more, the Danish giant has just announced a US$2-billion deal with Chinese pharmaceutical company United Biotechnology, to license it's novel weight-loss and diabetes drug UBT251 to the ...

According to deal terms announced Monday, Novo Nordisk is paying United Biotechnology $200 million up front for global rights to its drug, UBT251. United Biotechnology retains rights to the ...

With the United Lab deal, it has gained the rights to develop, manufacture and sell its experimental drug, UBT251. UBT251 belongs to a class of drugs that target a combination of gut and ...

The candidate at the center of the deal, dubbed UBT251, is a triple agonist for glucagon-like peptide-1 (GLP-1), gastric inhibitory polypeptide (GIP) and glucagon. Wegovy already inhibits GLP-1 ...

Novo Nordisk has acquired the global rights to China-based United Laboratories’ triple-agonist weight-loss and diabetes drug in a deal worth up to $2bn as the Wegovy (semalgutide) developer ...

Novo Nordisk and United Laboratories International’s subsidiary, United Biotechnology Co. have entered into a potentially $2 billion license agreement for UBT251, a glucagon triple-receptor ...

Under the license agreement, Novo Nordisk will obtain exclusive worldwide rights (excluding Chinese mainland, Hong Kong, Macau, and Taiwan) to develop, manufacture, and commercialize UBT251.